CLAIMS

1. Use of a compound in the manufacture of a medicament for use in treating a disease or disorder, wherein the compound is  or a pharmaceutically acceptable salt thereof; and the medicament comprises 25-500 mg of the compound.

2. The use of claim 1, wherein the medicament is for conjoint administration with a BCL-2 inhibitor.

3. The use of claim 2, wherein the BCL-2 inhibitor is venetoclax.

4. The use of claim 3, wherein the venetoclax is for administration at a daily dose of 400 mg.

5. The use of any one of claims 1-4, wherein the medicament is for conjoint administration with a BTK inhibitor.

6. The use of claim 5, wherein the BTK inhibitor is ibrutinib, acalabrutinib, zanubrutinib, evobrutinib, tirabrutinib (ONO-4059), spebrutinib, or poseltinib (HM7 1224).

7. The use of claim 6, wherein the BTK inhibitor is acalabrutinib.

8. The use of claim 7, wherein the acalabrutinib is to be administered at a daily dose of 200 mg.

9. The use of claim 6, wherein the BTK inhibitor is ibrutinib.

10. The use of claim 9, wherein the ibrutinib is to be administered at a daily dose of 420 mg or 560 mg.

11. The use of claim 6, wherein the BTK inhibitor is zanubrutinib.

12. The use of claim 11, wherein the zanubrutinib is to be administered twice daily at a dose of 160 mg or 320 mg.

13. The use of any one of claims 1-12, wherein the medicament is for administration twice per day, and each dose of the medicament comprises about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg of the compound .

14. The use of any one of claims 1-12, wherein the medicament is for administration once per day, and each dose of the medicament comprises about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg of the compound.

15. The use of any one of claims 1-12, wherein the medicament is for administration twice per day, and each dose of the medicament comprises about 200 mg of the compound.

16. The use of any one of claims 1-12, wherein the medicament is for administration twice per day, and each dose of the medicament comprises about 300 mg of the compound.

17. The use of any one of claims 1-16, wherein the medicament is for conjoint administration with an additional anti-cancer therapy.

18. The use of claim 17, wherein the additional anti-cancer therapy comprises a PD-1 inhibitor, a PD-L1 inhibitor, a hypomethylating agent, or a combination thereof.

19. The use of any one of claims 1-18, wherein the disease or disorder is a cancer.

20. The use of any one of claims 1-19, wherein the disease or disorder is a hematological malignancy.

21. The use of claim 20, wherein the hematological malignancy is leukemia, lymphoma, non-Hodgkin's lymphoma, myelogenous leukemia, myeloid leukemia, acute myeloid leukemia, myelodysplastic syndrome, lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), ABC-DLBLC, GCB-DLBLC, mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), multiple myeloma, marginal zone lymphoma (MZL), Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, extranodal marginal zone B cell lymphoma, transformed high grade B-cell lymphoma (HGBL), lymphoplasmacytic lymphoma (LPL), central nervous system lymphoma (CNSL), or MALT lymphoma.

22. The use of claim 20, wherein the hematological malignancy is relapsed or refractory.

23. The use of claim 21, wherein the hematological malignancy is follicular lymphoma.

24. The use of claim 21, wherein the hematological malignancy is diffuse large B-cell lymphoma (DLBCL).

25. The use of claim 21, wherein the hematological malignancy is activated B cell-like (ABC) DLBCL.

26. The use of claim 21, wherein the hematological malignancy is Waldenstrom's macroglobulinemia (WM).

27. The use of claim 21, wherein the hematological malignancy is marginal zone lymphoma.

28. The use of claim 21, wherein the hematological malignancy is lymphoplasmacytic lymphoma (LPL).

29. The use of claim 21, wherein the hematological malignancy is CNS lymphoma.

30. The use of claim 29, wherein the CNS lymphoma is primary CNS lymphoma (PCNSL).

31. The use of any one of claims 1-18, wherein the disease or disorder is an inflammatory disease or disorder or an autoimmune disease or disorder.

32. The use of any one of claims 1-31, wherein the medicament is for administration to a subject having one or more of: a mutation in RICTOR, a N1065S mutation in RICTOR, a mutation in MYD88, a L265P mutation in MYD88, a mutation in CXCR4, or a mutation in TET2.

33. The use of any one of claims 1-32, wherein, following administration of the medicament to a subject, the subject's cytokine production decreases; optionally wherein IL-1 induced signaling decreases.

34. The use of any one of claims 1-33, wherein the medicament is for continuous administration.

35. The use of any one of claims 1-33, wherein the medicament is for continuous administration interrupted by one or more drug holidays, and wherein each drug holiday lasts for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days.

36. The use of claim 35, wherein the medicament is for administration daily for three weeks followed by a one-week drug holiday

37. The use of claim 36, wherein the medicament is for administration that continues cycling between three-week periods of continuous administration and one-week drug holidays until a change of disease state is observed.

38. A pharmaceutical composition comprising 50 – 500 mg of a compound and a pharmaceutically acceptable excipient, wherein the compound is



or a pharmaceutically acceptable salt thereof.

39. The pharmaceutical composition of claim 38, comprising about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg of the compound.

40. The pharmaceutical composition of claim 38, comprising about 300 mg of the compound.

41. The pharmaceutical composition of any one of claims 38-40, wherein the pharmaceutical composition further comprises a diluent, a binder, a surfactant, a disintegrant, and/or a lubricant.

42. The pharmaceutical composition of any one of claims 38-41, wherein the pharmaceutical composition further comprises:
(i) a diluent comprising lactose monohydrate or microcrystalline cellulose; or a combination thereof;
(ii) a binder comprising hypromellose;
(iii) a surfactant comprising lauryl sulphate;
(iv) a disintegrant comprising croscarmellose; and/or
(v) a lubricant comprising stearate.

43. An integer number of unit dosage form(s) comprising the pharmaceutical composition of claims 38-42, wherein the integer number of the unit dosage forms supplies the entire dose of the medicament of any one of claims 1-37.

44. The unit dosage forms of claim 43, wherein 1, 2, 3, 4, 5, or 6 unit dosage forms supply the entire dose of the medicament.